Drug intelligence / Profile preview

SO-002(FTLD)-D

Development stage: Preclinical
Lead developer: SOICUM
Modality: Small Molecules

Overview

SO-002(FTLD)-D is a preclinical-stage small molecule derivative developed by SOICUM for the treatment of frontotemporal lobar degeneration (FTLD). The compound is designed to target TDP-43 (TAR DNA-binding protein 43) proteinopathy, a pathological hallmark of FTLD characterized by the abnormal aggregation and mislocalization of the TDP-43 protein. As a derivative of the SO-002 program, it is specifically optimized to address the neurodegenerative processes associated with TDP-43 dysfunction in the brain. The drug was identified through SOICUM's Drug-Target-Disease (DTD) database platform.

Targets

TARDBP (TAR DNA-binding protein 43)

Beyond the preview

Go deeper on SO-002(FTLD)-D.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SO-002(FTLD)-D.

Explore the full profile